COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma - European Medical Journal

COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses the results of the randomised, double-blinded, phase 3 COMBI-d trial, which compared the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>